Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”On the first day of 2026, I’m delighted to share one of my favourite pieces of work—published today in The Lancet Haematology and featured on the cover.
This Viewpoint introduces a practical decision matrix to help prioritise novel therapies for thalassemia—including disease-modifying and gene therapies—based on need, benefit, and risk, particularly in settings where access remains limited.
It also proposes realistic alternatives when standard options are not available.
The work builds on Thalassaemia International Federation guidelines, the best available trial and real-world evidence, and expert consensus from a truly global group of haematologists, transplant physicians, patient representatives, translational scientists, and trialists—bringing together 200+ years of collective clinical experience across Asia, the Middle East, Europe, and North America.
Grateful to an exceptional group of co-authors and hopeful this framework helps support more equitable, evidence-based care for patients worldwide.”
Read the full article in The Lancet Hematology.
Article: Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
Authors: Khaled Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 13:22Debra BenAvram: Every Two Seconds – Someone Needs Blood
-
Jun 15, 2026, 13:13Christina Ornauer: Exploring the Latest Advances in Hematology at EHA 2026
-
Jun 15, 2026, 13:05Angelo Zanniti: Back from EHA 2026 Congress
-
Jun 15, 2026, 12:56Chiara Pirillo: Building Global Connections at EHA 2026
-
Jun 15, 2026, 12:50Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
-
Jun 15, 2026, 12:46Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
-
Jun 15, 2026, 12:44Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
-
Jun 15, 2026, 12:31Chandrashekhar Athare: EHA 2026 Concludes with Lasting Impact and New Collaborations
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?